Maureen Durkin is professor and chair of population health sciences and Waisman Center investigator at the University of Wisconsin-Madison. She received her undergraduate degree and Ph.D. in anthropology from the University of Wisconsin-Madison and her M.P.H. and Dr.P.H. degrees in epidemiology from Columbia University. Her research focuses on the epidemiology of neurodevelopmental disabilities and childhood injuries, both globally and within the United States. She has collaborated in the development of cross-cultural methods for epidemiologic studies of developmental disabilities and methods for surveillance of childhood injuries and disabilities. She has also directed international studies on the prevalence and causes of neurodevelopmental disabilities in low-income countries. Durkin is currently a principal investigator in the Autism and Developmental Disabilities Monitoring Network and other projects related to public health surveillance, epidemiology and care integration of autism and other developmental disabilities.
Maureen Durkin
Professor of population health sciences
University of Wisconsin-Madison
Explore more from The Transmitter
Autism scientists push back on CDC’s inaccurate vaccine claims
The CDC website now falsely suggests that autism-vaccine research is still an open question, prompting distrust among researchers—some of whom anticipate “more unreliable statements coming from the junta that took over” the agency.
Autism scientists push back on CDC’s inaccurate vaccine claims
The CDC website now falsely suggests that autism-vaccine research is still an open question, prompting distrust among researchers—some of whom anticipate “more unreliable statements coming from the junta that took over” the agency.
Gene replacement therapy normalizes some traits in SYNGAP1 model mice
The first published virus-based gene therapy for SYNGAP1 deletion yields benefits despite the gene’s long length and complexity.
Gene replacement therapy normalizes some traits in SYNGAP1 model mice
The first published virus-based gene therapy for SYNGAP1 deletion yields benefits despite the gene’s long length and complexity.
Does AI understand what it produces? Henk de Regt explores how we might assess understanding in machines and humans
Building on his philosophy of how scientists understand what they work on, de Regt is extending his approach to test understanding in machines.
Does AI understand what it produces? Henk de Regt explores how we might assess understanding in machines and humans
Building on his philosophy of how scientists understand what they work on, de Regt is extending his approach to test understanding in machines.